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Abstract
Transfer of tumour antigen-specific receptors to T cells requires efficient delivery and integration of transgenes, and
currently most clinical studies are using gamma retroviral or lentiviral systems. Whilst important proof-of-principle data has
been generated for both chimeric antigen receptors and ab T cell receptors, the current platforms are costly, time-
consuming and relatively inflexible. Alternative, more cost-effective, Sleeping Beauty transposon-based plasmid systems
could offer a pathway to accelerated clinical testing of a more diverse repertoire of recombinant high affinity T cell
receptors. Nucleofection of hyperactive SB100X transposase-mediated stable transposition of an optimised murine-human
chimeric T cell receptor specific for Wilm’s tumour antigen from a Sleeping Beauty transposon plasmid. Whilst transfer
efficiency was lower than that mediated by lentiviral transduction, cells could be readily enriched and expanded, and
mediated effective target cells lysis in vitro and in vivo. Integration sites of transposed TCR genes in primary T cells were
almost randomly distributed, contrasting the predilection of lentiviral vectors for transcriptionally active sites. The results
support exploitation of the Sleeping Beauty plasmid based system as a flexible and adaptable platform for accelerated,
early-phase assessment of T cell receptor gene therapies.
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Introduction
Gamma retroviral-mediated transfer of recombinant receptors
to redirect T cell immunity against tumour and viral antigens is
being extensively investigated in early phase clinical trials.
Delivery of chimeric antigen receptors (CAR) against a variety
of target antigens, including CD19 in haematological malignan-
cies, GD2 in neuroblastoma and CEA in colonic carcinoma has
been reported and reviewed recently [1]. Similar vectors have
also been used to transfer conventional recombinant ab T cell
receptors against melanoma antigens [2]. Whilst there were
concerns that these vectors may mediate genotoxic side effects
in trials involving haematopoietic stem cell modification [3,4],
no vector related adverse events have been reported in T cell
studies [5]. Recently, HIV-1 derived lentiviral vector based T
cell redirection with a CAR against CD19 was reported [6],
and these vectors are thought to improve efficiency of gene
transfer and yield more functional T cells after ex-vivo
transduction. Previously, both retroviral [7] and lentiviral [8]
modification of T cells expressing recombinant T cell receptors
against the Wilm’s tumour (WT1) antigen has been described
and Phase 1 testing of an enhanced HLA-A2/WT1 peptide
specific TCR has been initiated. However, high-costs associated
with the manufacture of clinical grade viral vectors have been
limiting, and to date only a handful of viral vectors, with limited
target specificity have been produced. This limits applicability to
individuals with specific HLA types and substitution of existing
receptors with more efficacious derivatives is difficult. Alterna-
tively, more readily adaptable gene delivery platforms, capable
of mediating stable transgene integration without toxicity, could
accelerate clinical testing and extend applicability. Plasmid-
based gene transfer systems based on transposable elements are
under investigation of a variety of gene therapy applications.
The Sleeping Beauty (SB) platform [9] has been adapted to
transfer antigen-specific receptors to T cells [10–14], but direct
comparisons with lentiviral delivery are lacking. Here we have
assessed the ability of an enhanced Sleeping Beauty transposi-
tion system, using a hyperactive SB transposase named SB100X
[15] to deliver a codon optimised ab TCR against WT1
antigen. This HLA-A2 restricted receptor has been modified to
incorporate murine constant domains and additional disulphide
bonds to mitigate against aberrant cross-pairing with endoge-
nous TCR chains. Transduction efficiency, integration sites and
redirection of human primary T cells against WT1 antigen was
assessed and compared to lentiviral transduction procedures.
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Materials and Methods
Ethics Statement
Informed written consent was obtained from all healthy blood
sample donors with institutional ethics committee approval
(University College London, UK). All animals were handled in
strict accordance with good animal practice as defined by UK
Home Office Animal Welfare Legislation, and all animal work was
approved by the Institutional Research Ethics Committee
(University College London, UK) and performed under Home
Office approval (project license number 70/6482).
Cell Lines and Primary T Cells
Human leukaemic immortalized Jurkat cell lines (TCR nega-
tive) [16] and TAP (transporter associated with Ag processing)
deficient HLA-A0201+ T2 cell line [17] were maintained in
RPMI-1640 (Invitrogen, Paisley, UK) supplemented with 10%
heat-inactivated foetal calf serum (Sigma-Aldrich, Gillingham,
UK), and 1% penicillin/streptomycin (Invitrogen). Human
embryonic kidney 293T cells (ATCC CRL-11268TM) were
cultured in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% heat-inactivated foetal calf serum and 1%
penicillin/streptomycin. Human peripheral blood mononuclear
cells (PBMCs) were isolated from healthy HLA-A02 volunteers
(with institutional ethics committee approval) by density gradient
separation using Ficoll-Paque Plus (GE Healthcare, Little
Chalfont, UK) and were cultured in X-VIVO 10 (Lonza, Cologne,
Germany) supplemented with human AB serum (10%; Lonza) and
the human recombinant common c-chain cytokine IL2 (Chiron,
France).
Antibodies, Cytokines, Peptides and Flow Cytometry
Antibodies for flow cytometry were anti-human CD3 APC,
CD8 FITC, anti-mouse TCRb chain (mCb APC) (BD Bioscienc-
es, Cowley, UK); anti-human Vb2.1 PE and pWT126 tetramer
PE (Beckman Coulter, High Wycombe, UK). The antibodies used
for cytokine capture assay were IFNc catch reagent and anti-
human IFNc PE (Miltenyi Biotech, Germany). The concentration
of the human recombinant IL2 was 100 U/ml in all culture
conditions. The peptides used in this study were the HLA-A0201-
binding peptides pWT126 (RMFPNAPYL) and pWT235
(CMTWNQMNL), which were synthesized by ProImmune as
described previously [18]. Flow cytometric analysis was performed
using a LSR II flow cytometer (BDBiosciences) and the data were
analysed using FlowJo version 7 software (TreeStar, Ashland, OR,
USA).
Lentiviral and Sleeping Beauty Constructs
A self-inactivating lentiviral vector, encoding the SFFV (spleen
focus forming virus) LTR promoter and the HIV-1 central
polypurine tract sequence and mutated Woodchuck post tran-
scriptional regulatory element (WPRE) [19] was generated to
include a codon-optimized hybrid HLA-A0201-restricted WT1-
TCR genes [8]. The receptors comprise murine constant region
with additional disulphide bonds and human variable (Va1.5 and
Vb2.1) region sequences. The a and b chains are linked by a P2A
self-cleaving peptide sequence and the TCR recognises WT126
peptide, RMFPNAPYL in the context of HLA-A0201 [8]. The SB
transposon plasmid pT2/HB and hyperactive transposase plasmid
pCMV-SB100X have been previously described [15,20,21] and
were modified to encode an identical SFFV promoter WT1-TCR
cassette.
Lentiviral Vector Production
Lentiviral vector stocks were produced by transient co-
transfection of subconfluent HEK293T cells using polyethyleni-
mine (Sigma-Aldrich) with helper plasmids encoding vesicular
stomatitis virus (VSV) envelope plasmid (pMDG), and gag/pol
packaging plasmid (pCMVD8.74) as previously described [22].
Viral supernatant was harvested 48 and 72 hours later, 0.22 mM
filtered, and concentrated by ultracentrifugation before cryopres-
ervation. Vector stocks were titred on TCR negative Jurkat T cells
by flow cytometry.
Lentiviral Vector Transduction and Sleeping Beauty
Nucleofection
PBMCs were activated using magnetic beads conjugated to
antibodies to CD3 and CD28 (Invitrogen, Stockholm, Sweden), at
a ratio of 1:1 for 48 hours in X-VIVO 10 medium supplemented
with human AB serum and 100 U/ml IL2 [22]. The cells were
then exposed to lentiviral infection at a multiplicity of infection of
20 or nucleofected with DNA supercoiled plasmids (5 mg each)
encoding the SB transposon and the SB transposase, using an
Amaxa Nucleofector II device and Human T Cell Nucleofector
Kit and protocol for Stimulated Human T cells (Lonza). After 48–
72 hours after expression of TCR transgenes was analysed by flow
cytometry.
Expansion and Purification of TCR-modified T Cells
TCR modified T cells were either assessed immediately or
expanded weekly by antigen-specific stimulation in 24-well plates
as follows: 56105 TCR-transduced cells were co-cultured with
26105 T2 cells pulsed with pWT126 peptide as stimulators and
26106 irradiated autologous feeder PBMCs, in the presence of
100 U/ml IL2. In some experiments, WT1-TCR T cells were
expanded and then enriched by sorted by magnetic bead selection
using MiniMacs columns following two stage incubation with an
Figure 1. WT1-TCR vector constructs. A. Schematic representation
of the pSIN second-generation lentiviral (Lv) vector encoding the
codon-optimized, murinized hybrid HLA-A0201–restricted pWT126-
specific additional cysteines modified TCR a- and b-chain genes
separated by a self-cleaving porcine teschovirus 2A sequence (P2A).
LTR indicates long terminal repeat; m, murine SFFV, spleen-forming
focus virus; and WPRE, woodchuck hepatitis virus posttranscriptional
regulatory element. B. Schematic representation of the plasmid
Sleeping Beauty (SB) vector consisting of a transgene expression
cassette, encoding the codon-optimized, murinized hybrid HLA-A0201–
restricted pWT126-specific additional cysteines modified TCR a- and b-
chain genes separated by a self-cleaving porcine teschovirus 2A
sequence (P2A), flanked by inverted repeats; and the hyperactive SB
transposase SB100X. CMV indicates cytomegalovirus promoter; IL, left
inverted repeat; IR, right inverted repeat; m, murine; SFFV, spleen-
forming focus virus.
doi:10.1371/journal.pone.0068201.g001
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Figure 2. WT1-TCR expression and function in human primary T cells. A. WT1-TCR cell surface expression. Percentages of Vb2.1 positive cells
in CD8+ T cells for each HLA-A2+ donor are shown after WT1-TCR lentiviral (Lv) or Sleeping Beauty (SB) vector gene transfers. CD3/CD28 microbeads-
activated PBMCs were transduced at a multiplicity of infection of 20 or nucleofected with 5 mgs transposon and transposase plasmids. *p,0.05. B.
Antigen-specific effector function. Mean percentages of IFNc positive cells in CD8+ T cells from HLA-A2+ donors assayed by MACS Cytokine Secretion
Assay of human primary CD8+ T cells, after WT1-TCR lentiviral (Lv) or Sleeping Beauty (SB) vector gene transfer, restimulated with either the specific
WT1 peptide, anti-CD3 Ab (positive control) or irrelevant peptide (negative control), and autologous PBMCs (top). Representative dot plots of IFNc
secretion are also shown after WT1-TCR Lv (bottom left) or SB (bottom right) gene transfer.
doi:10.1371/journal.pone.0068201.g002
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Figure 3. Antigen-specific responses of human primary T cells. A. Murine Cb/human Vb2.1 expression and WT1 tetramer binding are shown
in representative human primary lymphocyte dot plots, after SFFV-driven WT1-TCR lentiviral vector (Lv) or Sleeping Beauty (SB) gene transfer and in
unmodified controls. CD3/CD28 microbeads-activated PBMCs were transduced at a multiplicity of infection of 20 or nucleofected with 5 mgs
transposon and transposase plasmids and expanded with T2 cells coated with specific peptide pWT126 and irradiated autologous PBMCs as feeder
cells. B. In vitro cytotoxicity of donor T cells against specific peptide-loaded T2 target cells, Lv versus SB. Percentages of cytolytic activity of T cells,
after WT1-TCR lentiviral (Lv) or Sleeping Beauty (SB) vector gene transfers, was tested in a 51Cr release CTL assay. CD3/CD28 microbeads-activated
PBMCs were transduced at a multiplicity of infection of 20 or nucleofected with 5 mgs transposon and transposase plasmids and expanded with the
specific WT1 peptide and autologous irradiated PBMCs. Both WT1-TCR-modified donor T cells recognized and killed their specific targets (2 way
ANOVA, p,0.001 at all E:T ratios compared to GFP-modified or unmodified cells).
doi:10.1371/journal.pone.0068201.g003
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anti-murine TCRb chain APC antibody, followed by anti-APC
microbeads (Miltenyi Biotech).
Cytotoxicity Assays
In vitro 51Cr release cytotoxicty assays were performed with
26106 T2 cells pre-incubated at 37uC for 1 hour in 200 ml assay
medium (RPMI 1640 containing 5% heat-inactivated FCS) with
100 mM specific peptide as target cells. Peptide-coated T2 cells
were then labelled with 51Cr for 1 hour, washed, and added to
serial 2-fold dilutions of expanded WT1-TCR modified PBMCs as
effector cells in round-bottom 96-well plates to obtain a total
volume of 200 ml/well. Assay plates were incubated at 37uC, 5%
CO2, and after 4 hours, 50 ml supernatant was harvested and
radioactivity counted. The specific killing was calculated by the
equation: (experimental release-spontaneous release)/(maximum
release-spontaneous release)6100%.
In vivo cytotoxicity assays were performed with 0.76106 WT1-
TCR modified splenocytes from C57Bl/6 mice as effector cells,
which were activated with Concanavalin A 2 mg/ml (Sigma-
Aldrich) and IL2 100 U/ml for 3 days in RPMI 1640 containing
10% heat-inactivated FCS, 0.1 mM 2-mercaptoethanol (Invitro-
gen) and 0.1 mM sodium pyruvate (Lonza) and nucleofected with
the SB transposon and the SB transposase DNA plasmids, using an
Amaxa Nucleofector II device and Mouse T Cell Nucleofector Kit
and protocol (Lonza). The effector cells were injected intrave-
nously into A2Kb mice without conditioning and left 2 days to
equilibrate. Splenocytes from female A2Kb Tg mice were
prepared as target cells by selecting B cells (B Cell Isolation Kit;
Miltenyi Biotec), peptide-loaded with 100 mM of either specific
peptide (WT126p) or an irrelevant HLA-A0201-presented peptide
before labelling with 1.5 mM or 0.15 mM CFSE, respectively, for 5
minutes at 37uC. Labelled cells were mixed at a 1:1 ratio, relevant:
irrelevant targets and a total of 106106 mixed cells were injected
into recipient A2Kb mice previously injected with effector cells.
Eighteen hours later, splenocytes of injected animals were
analyzed by flow cytometry to identify CFSE-labelled cells.
Control untreated A2Kb Tg mice were injected with labelled
target cells only and in vivo cytotoxicity was calculated as
previously described. Percentage antigen-specific cytotoxicity was
determined using the following formula: [1- (mean number of
relevant peptide-loaded targets in experimental mice/mean
number of irrelevant peptide-loaded targets in experimental
mice)/(mean number of relevant peptide-loaded targets in control
mice/mean number of irrelevant peptide-loaded targets in control
mice )]6100.
Figure 4. In vivo cytotoxicity of murine primary T cells. In vivo cytotoxicity of modified mouse splenocytes against CFSE-labelled peptide-
loaded mouse target B cells. A2Kb Tg mice, 2 days after intravenous injection of syngeneic effector cells modified with Sleeping Beauty (SB) WT1-TCR
vector system, were again intravenously injected with a 1:1 mix of relevant: irrelevant peptide-loaded A2Kb Tg target B cells, differentially labelled
with CFSE (specific WT126 peptide, 1.5 mM CFSE, and irrelevant WT235 peptide for WT1-TCR, 0.15 mM CFSE). Eighteen hours later, splenocytes of
injected animals were harvested and analysed by FACS to identify CFSE-labelled cells. Control A2Kb Tg mice were injected with only CFSE-labelled
peptide-loaded target B cells or with unmodified splenocytes as effectors. Antigen-specific cytotoxicity was calculated as [1- (number of relevant
peptide-loaded targets in experimental mice/number of irrelevant peptide-loaded targets in experimental mice)/(number of relevant peptide-loaded
targets in control mice/number of irrelevant peptide-loaded targets in control mice )]6100.
doi:10.1371/journal.pone.0068201.g004
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C57Bl/6 mice were purchased from Charles River (Margate,
UK). HLA-A0201Kb transgenic (A2Kb Tg) mice on a C57Bl/6
background were a kind gift from Theobald M. (University
Medical Center, Utrecht, The Netherlands) and were bred and
maintained in the Comparative Biology Unit of University College
London (Royal Free Hospital, London, UK) under pathogen-free
conditions.
Ligation-mediated PCR (LM-PCR)
To recover integration sites, DNA from WT1-TCR modified
PBMCs by lentiviral transduction or SB nucleofection was
extracted by Proteinase K digestion. 1 mg of DNA was digested
with NlaIII to produce vector-chromosome junction fragments,
ligated to excess linker and PCR was performed with GoTaq
polymerase (Promega, Madison, WI) using the linker first-round
and second-round primers as previously described [20,21]. PCR
products were shotgun-cloned into the Topo-TA vector (Invitro-
gen) and sequenced (UCL, London, UK) using the second round
primers. LM-PCR products were 454 pyrosequenced as previously
described [21].Raw sequence reads obtained after sequencing
were trimmed and aligned to the human genome (NCBI, hg19)
using HISAP [23]. Integration sites were considered to be valid if
vector-genome junction sequence was present and the flanking
genomic region had a unique sequence match of at least 95% after
alignment to the human genome (University of California at Santa
Cruz, RefSeq genes and RepeatMasker). Chromosome graphs
were generated using the University of California at Santa Cruz
Genome Graphs tool.
Statistics
Where shown, error bars represent the standard error of the
mean of the replicates indicated, and differences were found to be
significant by application of non-parametric Anova tests.
Results
1. Sleeping Beauty Mediated ab TCR Transfer to Primary
T Cells Compared to Lentiviral Delivery
Sleeping Beauty transposon-mediated TCR delivery was
compared against lentiviral vector-mediated gene transfer in
primary human lymphocytes using identical promoter/transgene
expression cassettes. These comprised an optimised human-
murine chimeric WT1 abTCR encoding Va1.5 and Vb2.1 chains
[8] in combination with the spleen-forming focus virus (SFFV)
long terminal repeat promoter (Figure 1A, B). Sleeping Beauty
transposons were delivered in combination with a functionally
enhanced, hyperactive, Sleeping Beauty transposase variant,
SB1006 (Figure 1B). Preliminary experiments in TCR-deficient
Jurkat T cells allowed optimisation of transposon/SB100X
plasmid ratios, and confirmed robust and durable expression
following both lentiviral and SB delivery.
Freshly isolated human peripheral blood lymphocytes (PBL)
from healthy HLA-A2 donors were stimulated for 48 hours with
anti-CD3/CD28 microbeads and human IL-2 then exposed to a
single round of lentivirus infection or nucleofected with transpo-
son/transposase DNA plasmids. Flow cytometry following staining
with anti-Vb2.1 antibody identified primary T cells expressing cell
surface WT1-TCR and revealed comparable gene transfer. These
investigations using multiple healthy volunteer donor lymphocytes
revealed inter-individual variability, with mean levels of SB
mediated gene transfer in CD8+ T cells of 10.5% (n= 10)
compared to 11.4% (n= 5) following lentiviral transduction
(Figure 2A). These engineered CD8+ T cells were pulsed with
HLA-A2 restricted WT1 peptide and antigen-specific responses
were confirmed on the basis of IFNc release (Figure 2B). Assuming
that WT1 specific responses were only mediated by WT1-TCR
expressing cells, events captured by flow cytometry within the
CD8+IFNc+ gate (1.4% for LV, 2.3% for SB) accounting for 28%
and 57% of the modified populations respectively. Furthermore,
WT1-TCR-modified T cell populations could be expanded and
were then subjected to challenge by peptide loaded target cells.
Co-staining for murine TCRb chain epitopes distinguished
recombinant receptor expression from endogenous Vb2.1 expres-
sion and HLA-A2/pWT126 multimer staining confirmed WT1-
specific TCR expression (Figure 3A). Human TAP-deficient T2
target cells loaded with pWT126 peptide were specifically lysed by
both lentiviral and SB modified T cells, in contrast to cells
presenting non-relevant peptides or cultures challenging control
(eGFP) modified T cells (Figure 3B).
2. In vivo Functional Assessment of SB Modified T Cells
Assessments of TCR redirected human T cells in immunode-
ficient mice injected with human WT1 expressing tumour cells
have previously demonstrated the potency of retroviral modified T
cells in vivo, including T cell homing and tumour eradication.
However, these models are technically challenging with variable
reproducibility. Alternatively A2Kb transgenic mice have been
used to assess the function of T cells derived from murine stem
cells modified using lentiviral vectors to express HLA-A2/WT1
specific TCRs [24]. Mature murine T cells resist lentiviral
transduction through the expression of innate restriction factors
[25] but we successfully adopted the model for confirmation that
SB modified murine T cells expressing human TCR specific for
HLA-A2/WT1 are functional in vivo. Activated splenocytes from
C57Bl/6 mice were nucleofected with the SB transposon system
expressing WT1-TCR and were injected into unconditioned
recipient A2Kb transgenic mice. Two days later, target B cells
from female A2Kb Tg mice were peptide-loaded with relevant
(pWT126) or irrelevant HLA-A2-restricted peptides and labelled
with CFSE. Labelled target with relevant or non-relevant targets
were mixed at a 1:1 ratio and were injected in the same recipient
mice. Eighteen hours later, splenocytes of injected animals were
analysed by flow cytometry to identify CFSE-labelled target cells.
Figure 5. Integration profiles in human primary T cells by LM-PCR. CD3/CD28 microbeads-activated PBMCs were transduced at a multiplicity
of infection of 20 (Lv) or nucleofected with both 5 mgs transposon and transposase plasmids (SB). Both vectors encoded the identical WT1-TCR
transgene. Genomic DNA was extracted and lentivirus-chromosome or transposon-chromosome junctions were recovered by ligation-mediated PCR
and sequenced. A. Genome-wide mapping of vector integrations at the chromosome level. Sequences were mapped to the University of California at
Santa Cruz (UCSC) human genome by BLAT search and integration sites were depicted relative to chromosomes using the UCSC Genome Graphs
tool. Lv in Blue, SB in Red. B. Frequency of integration sites of vectors within RefSeq genes. 1,000 random integration sites were generated by
bioinformatics, as already described [21]. C. Proximity of integration sites to transcription start sites (TSS). RefSeq genes containing integration sites
were divided by length into 4 equally sized regions and 1 upstream region (0–5 kb), and the proportion of integration sites within each region was
counted. To allow statistical comparison of integration preferences with average genomic content, 1,000 random chromosomal sites were generated
by multiplying the total length of the genome by a random number between 0 and 1 and converting this value to a chromosomal coordinate. Vector
integration frequencies are expressed relative to the proportion of random sites within each region.
doi:10.1371/journal.pone.0068201.g005
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Control (untreated) A2Kb Tg mice were injected with only labelled
target cells (Figure 4). In vivo, target specific cytotoxicity ranged
from 26–53%, confirming antigen-specific function of SB modified
T cells.
3. Sleeping Beauty Transposition Sites in Primary Human
T Cells
Lentiviral integration sites in T cells have been well char-
acterised in subjects with HIV-1 infection and in gene engineered
T cells and there is a preference for integration in transcriptionally
active regions, though in contrast to gamma-retroviral vectors, no
bias towards transcription start sites (TSS). Sleeping Beauty
transposons target TA dinucleotides and are thought not to target
gene coding sequences. Integration sites (n$150) of lentiviral
vectors and SB transposons expressing WT1-TCR transgenes
were detected by high throughput sequencing. Overall, 70.8% of
lentiviral integrations were found within genes compared to 40.2%
of SB100X/transposon-mediated transgene insertions, which was
more comparable to anticipated frequencies of 34.2% if random
integration had occurred (Figure 5B). When integrations within
genes were mapped relative to their position within the gene or
upstream region (Figure 5C), no preference toward TSS of RefSeq
genes was observed along the length of the gene and no significant
variation in integration pattern was observed along the length of
the gene. The bias towards RefSeq genes can be expressed as a
ratio of frequencies in genes above random, and this yielded values
of 2.05 for lentiviral vectors and 1.17 for the SB platform. Thus, in
primary human lymphocytes plasmid-based SB delivery of
abTCR gene expression cassettes appears less likely to perturb
endogenous gene function.
Discussion
Wilms’ Tumour antigen 1 (WT1) is a well characterised tumour
antigen overexpressed by haematological and certain non-haema-
tological malignancies. A phase 1 study of gamma retrovirally
modified T cells to treat relapsed leukaemia has recently been
initiated to investigate the safety and efficacy of a recombinant ab
TCR specific for HLA-A2/WT1 peptide antigen (ClinicalTrials.-
gov; NCT01621724). As with other T cell modification therapies
requiring stable transgene integration, a major hurdle has been the
production and validation of clinical grade vector stocks. In the
case of gamma-retroviral vectors, efficient stable packaging cell
lines have facilitated the production of large volumes of vector
stocks, and yet the very high levels of investment required have
meant only a handful of candidate antigen-specific receptors have
been adopted for translational studies. Recent advances support a
switch to lentiviral vector platforms [22,26], but GMP production
of high titre lentiviral stocks is problematic and is hampered by the
lack of stable producer lines. Rather, lentiviral stocks are produced
by transient transfection, using high quality plasmids and then
require extensive and costly downstream validation and release
testing. The availability of an alternative plasmid based system for
direct modification of T cells would allow accelerated assessment
of different TCRs and revised CAR configurations. In this regard
transposon-based systems are attractive and proposals for initial
clinical testing of a nucleofection-based protocol for transfer of a
CD19 specific CAR are well developed [14,27,28]. The enhanced
SB100X mutant has been evaluated for transfer of a similar single
chain receptor, but information on delivery of a ab TCR
configuration has been lacking. We have demonstrated stable
gene transfer by SB100X-mediated transposition, and have
determined that integration sites in primary human T cells are
similar to those reported for human cell lines, and are not skewed
towards gene rich, transcriptionally active loci. We speculate that
this may reduce the risk of genotoxicity, albeit noting that there
have been no vectors-mediated adverse events in any gamma
retroviral or lentiviral studies targeting human T cells even when
integrants close to protoncogenes have been detected. We
speculate that this relates to the differentiated nature of T cells,
in contrast to haematopoietic stem cells where risks of transfor-
mation may be greater. There have been concerns that
background integration of transposase encoding plasmid may
mediate remobilisation of transposed sequences, and this could
also be a risk factor for mutagenesis. Strategies to mitigate against
such eventualities include the use of mRNA rather than plasmid
for transposase delivery [11], or the incorporation of a linked
suicide gene for elimination of cells in case of adverse effects [22].
Whilst transposition may be less efficient than lentiviral-mediated
gene transfer, we have demonstrated the feasibility of enriching
cells by magnetic bead selection and expanding antigen-specific
populations using stimulator cells and feeder layers if high
numbers of cells are required [14,29]. Alternatively, it is entirely
possible that the early reinfusion of fewer SB modified T cells,
cultured for a shorter period and retaining functional properties
may be sufficient to mediate beneficial in vivo effects.
In summary, SB-mediated transfer of antigen-specific T cell
receptor redirects effector function and offers a flexible pathway
for rapid evaluation of different receptor configurations. Further
optimisation and adaptation to GMP conditions will allow
therapeutic applications to be explored in early phase clinical
studies.
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